stella
beta
A Phase I/IIa, Open-label, Single-center, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of IMV101 as a Single Agent in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma — Stella
Recruiting
Back to Relapsed/Refractory B-cell Non-Hodgkin Lymphoma trials
Early Phase 1 — The very first tests in people. Usually just a handful of volunteers, to check the treatment is safe enough to keep studying.
Trial locations
(4 sites)
China
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing Municipality
Beijing GoBroad Boren Hospital, Beijing, Beijing Municipality
Zhengzhou Yihe Hospital, Zhengzhou, Henan
The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang
View full record on ClinicalTrials.gov